New developments in the imaging of metastatic prostate cancer

Current Opinion in Supportive and Palliative Care

Volumn 8, Issue 3, 2014, Pages 265-270

  Beauregard, Jean Mathieu ^a,b   Pouliot, Frédéric ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b University Laval   (Canada)

Author keywords

Castration resistance; Metastasis; MRI; PET; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER;

CANCER STAGING; HUMAN; MALE; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

BIOLOGICAL MARKERS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MOLECULAR IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84905719181     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000076     Document Type: Review

References (36)

1. Gomella LG, Petrylak DP, Shayegan B. Current management of advanced and castration resistant prostate cancer. Can J Urol 2014; 21:1-6.
2. Hövels AM, Heesakkers R, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008; 63:387-395.
3. Evangelista L, Zattoni F, Guttilla A, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and metaanalysis. Clin Nucl Med 2013; 38:305-314.
4. Evangelista L, Guttilla A, Zattoni F, et al. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 2013; 63:1040-1048.
5. Jadvar H. Molecular imaging of prostate cancer with PET. J Nucl Med 2013; 54:1685-1688.
6. 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun 2013; 34:935-945.
7. Scher HI, Halabi S, Tannock I, et al., Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148-1159.
8. Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011; 17:4854-4861.
9. Heesakkers RAM, Hövels AM, Jager GJ, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008; 9:850-856.
10. Van den Bergh RC, Ahmed HU, Bangma CH, et al. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur Urol 2014; 65:1023-1031.
11. Murphy G, Haider M, Ghai S, Sreeharsha B. The expanding role of MRI in prostate cancer. AJR Am J Roentgenol 2013; 201:1229-1238.
12. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348:2491-2499.
13. Birkhäuser FD, Studer UE, Froehlich JM, et al. Combined ultrasmall super paramagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol 2013; 64:953-960.
14. Padhani AR, Makris A, Gall P, et al. Therapy monitoring of skeletal metastases with whole-body diffusion MRI. J Magn Reson Imaging 2014; 39:1049-1078.
15. Pasoglou V, Larbi A, Collette L, et al. One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified 'all-in-one' imaging approach? Prostate 2014; 74:469-477.
16. 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 2012; 62:68-75.
17. 18F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer. J Med Imaging Radiat Oncol 2010; 54:325-332.
18. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008; 54:392-401.
19. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010; 254:925-933.
20. 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med 2013; 54:833-840.
21. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. Eur J Nucl Med Mol Imaging 2014; 41:878-886.
22. 18F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging 2013; 40:1356-1364.
23. 11C-choline positron emission tomography in recurrent prostate cancer. World J Urol 2013; 31:319-323.
24. 18F-fluoride PET/ CT. J Nucl Med 2006; 47:287-297.
25. 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry. J Nucl Med 2014; 55:574-581.
26. 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int 2012; 110:1501-1506.
27. Vargas HA, Wassberg C, Fox JJ, et al. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology 2014; 271:220-229.
28. 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 2014; 41:887-897.
29. Buchegger F, Garibotto V, Zilli T, et al. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. Eur J Nucl Med Mol Imaging 2014; 41:68-78.
30. 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. Eur J Nucl Med Mol Imaging 2013; 40 (Suppl. 1):S11-S17.
31. Osborne JR, Green DA, Spratt DE, et al. A prospective pilot study of (89)zrj591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol 2014; 191:1439-1445.
32. Wetter A, Lipponer C, Nensa F, et al. Quantitative evaluation of bone metastases from prostate cancer with simultaneous [F] choline PET/MRI: combined SUV and ADC analysis. Ann Nucl Med 2014; 28:405-410.
33. 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med 2013; 54:1195-1201.
34. 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res 2010; 16:6093-6099.
35. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy. J Nucl Med 2014; 55:233-241.
36. 18F-fluorocholine PET/CT in castration-resistant prostate cancer. J Nucl Med 2014; 55:905-910.